Nymox Pharmaceutical Corporation

NYMXF · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$4,492-$8,844-$6,576-$12,537
Dep. & Amort.$1$11$12$12
Deferred Tax$0$0$0$0
Stock-Based Comp.$671$3,357$593$2,603
Change in WC$1,219$821$495-$140
Other Non-Cash$0$598$509$3,027
Operating Cash Flow-$2,601-$4,057-$5,205-$9,820
Investing Activities
PP&E Inv.$0-$3$0-$6
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0-$3$0-$6
Financing Activities
Debt Repay.$2,605$1,750-$229-$238
Stock Issued$0$1,150$6,007$7,283
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$173$0$0
Financing Cash Flow$2,605$2,727$5,778$7,045
Forex Effect$0$0$0$0
Net Chg. in Cash$4$1,333$573-$2,781
Supplemental Information
Beg. Cash$70-$1,403$830$3,611
End Cash$74-$70$1,403$830
Free Cash Flow-$2,601-$4,060-$5,205-$9,826
Nymox Pharmaceutical Corporation (NYMXF) Financial Statements & Key Stats | AlphaPilot